2. Search Result
Search Result
Results for "

TF1

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Inhibitory Antibodies

3

Recombinant Proteins

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155951
    JAK3-IN-14

    		JAK Cancer
    JAK3-IN-14 (compound 1) is a potent JAK3 inhibitor, with IC50 values of 38 and 600 nM for JAK3 and JAK2, respectively. JAK3-IN-14 shows inhibitory of IL-4 and IL-3 induced TF-1 cell proliferation, with IC50 values of 600 and 500 nM, respectively [1].
    JAK3-IN-14
  • HY-P990090
    Rademikibart

    CBP-201

    		 Interleukin Related Inflammation/Immunology
    Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research [1].
    Rademikibart
  • HY-100388B
    SHP099 hydrochloride

    		SHP2 Cancer
    SHP099 hydrochloride is an allosteric SHP2 inhibitor, with IC50s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2 D61Y, SHP2E69K, SHP2 A72V, SHP2 E76K. SHP099 hydrochloride inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC50: 0.32 and 1.73 μM). SHP099 hydrochloride inhibits RAS-ERK signaling and inhibit tumor growth [1] .
    SHP099 hydrochloride
  • HY-156158
    IDH2R140Q-IN-2

    		Isocitrate Dehydrogenase (IDH) Cancer
    IDH2 R140Q-IN-2 (compound 36) is an an orally active IDH2 R140Q inhibitor (IC50: 29 nM). IDH2 R140Q-IN-2 reduces D2HG production in TF-1 cell lines expressing mutant IDH2 R140Q (IC50: 10 nM). IDH2 R140Q-IN-2 suppresses D2HG levels in tumor tissue. IDH2 R140Q-IN-2 can be used for research of acute myeloid leukemia (AML) [1].
    IDH2R140Q-IN-2
  • HY-151285
    JAK-2/3-IN-3

    		Apoptosis JAK Inflammation/Immunology Cancer
    JAK-2-/3-IN-3 (compound ST4j) is a potent JAK2/3 inhibitor with IC50s of 13.00 and 14.86 nM for JAK2 and JAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation of JAK2 and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia [1].
    JAK-2/3-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: